Gates Foundation Strategic Investment Fund Logo
Share this page:


									Synlogic Logo

Synlogic is a start-up company in Boston, developing a first-in-class synthetic biology platform for genetically engineering bacteria of the microbiome for delivery of therapeutics to the gut, initially focused on metabolic imbalance and inflammatory disease. This technology has potential for application to several diarrheal diseases, including pathogens such as Cryptospordium, Shigella, and Entertoxigenic E. Coli. The foundation’s investment supported development of a specific global health product for the treatment of diarrheal disease.

Investment Date: January 2014